ESC Professional Premium Access

Chronic heart failure - Pharmacotherapy

Event: ESC Congress 2022
Topic: Pharmacotherapy
Session type: Moderated ePosters
Date: 27 August 2022
Time: 09:15 - 09:40

Congress Session

5 presentations in this session

Dapagliflozin utilization following hospitalization for heart failure: real-world insights from EVOLUTION HF, a multinational, observational study

Speaker: Associate Professor G. Savarese (Stockholm, SE)
Thumbnail

Direct effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial

Speaker: Doctor C. Andersen (Herlev, DK)
Thumbnail

Acute effect of empagliflozin on serum uric acid - a subanalysis of the EMPAG-HF trial (effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure)

Speaker: Mr J. Bogoviku (Jena, DE)
Thumbnail

Real-world eligibility and cost-effectiveness analysis for empagliflozin in patients with heart failure

Speaker: Doctor E. Kim (Daejeon, KR)
Thumbnail

Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction - EMPEROR-Preserved trial

Speaker: Professor M. Boehm (Homburg, DE)
Thumbnail

5 speakers from this session

Associate Professor Gianluigi Savarese

Karolinska Institute, Stockholm (Sweden)
16 presentations
0 follower

Doctor Camilla Fuchs Andersen

Herlev Hospital, Herlev (Denmark)
0 follower

Mr Jurgen Bogoviku

University hospital Jena, Jena (Germany)
1 presentation
0 follower

Doctor Eui-Soon Kim

Korea Advanced Institute of Science and Technology, Daejeon (Korea (Republic of))
0 follower

Professor Michael Boehm

Saarland University Hospital, Homburg (Germany)
58 presentations
1 follower

This platform is supported by

logo Novo Nordisk